Engflag

Candid powder

Quick links to important sections

Candid powder

Candid powder_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Candid powder

Property Description
Active ingredient Clotrimazole (1% w/w)
Form Dusting Powder (Topical preparation)
Pharmacological class Azole Antifungal
Common use Mitigating superficial fungal skin infections
Origin Synthetic imidazole derivative

Defining Candid Powder: Identity and Classification

Candid powder is a topical pharmaceutical preparation whose single active ingredient is Clotrimazole, officially classified as an azole antifungal medication. This medicine is a synthetic imidazole derivative specifically designed for external use to address common skin conditions caused by fungal organisms.

Clotrimazole, the International Nonproprietary Name (INN) for the compound, places it within a family of antimycotic agents recognized for their broad-spectrum activity against a wide range of dermatophytes and yeasts. The product's positioning as a dusting powder differentiates it from cream or lotion formulations, particularly targeting conditions like athlete's foot where moisture control is essential. The substance is a derivative of imidazole and is active against Candida and Tinea species.

Form, Composition, and General Purpose

The product is provided as a specialized dusting powder, a suitable dosage form for topical administration on the skin. The formulation typically delivers 1% w/w Clotrimazole USP evenly distributed within an inert powder base, often containing components like Talc BP or Zinc Oxide BP. This composition is recognized for its ability to combine drug delivery with moisture absorption.

This powder form offers a dual functional benefit: it delivers the active Clotrimazole directly to the affected area, and simultaneously, the inert base acts to absorb excess moisture and sweat. This moisture-management function is critical, as a dry environment is less conducive to fungal proliferation, thereby easing the discomforts of chafing and dampness. Azole topical preparations function by altering the cell membrane permeability of fungal cells.

How Clotrimazole Fights Fungi at a High Level

Clotrimazole’s primary function is both fungistatic (stopping growth) and, in sufficient concentration, fungicidal (eliminating the fungi) by disrupting the fungal cell structure. The medication works by preventing the fungus from properly constructing and maintaining its cell membrane, which is essential for fungal survival.

This highly specific mechanism, common to the azole class, focuses on the cessation of fungal growth and elimination. The ultimate objective is the resolution of the underlying fungal pathogen, allowing for the natural restoration of a healthy cutaneous barrier and providing effective relief from the symptoms associated with persistent, moisture-related fungal infections.

What side effects are possible with Candid powder?

Possible Side Effects and Safety Information

The safety profile of Candid powder, whose active ingredient is Clotrimazole, is based on the classification of adverse reactions documented in official regulatory sources.

Most documented side effects are localized, reflecting the product's use as a topical antifungal with minimal systemic absorption.

Regulatory Classification of Adverse Reactions

Classification Scope Details from Regulatory Documents
Common Adverse Reactions Local reactions at the application site, including burning or stinging sensation, erythema (redness), pruritus (itching), and general irritation or pain.
System-Organ Classes Primarily Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions. Immune System Disorders are documented under serious reactions.
Serious Adverse Reactions Rare instances of severe Hypersensitivity reactions, including anaphylaxis and angioedema (swelling), have been officially reported.

Population-Specific and Use Constraints

The safety profile includes specific considerations for certain populations. Due to minimal absorption, use during the second and third trimesters of pregnancy is not typically associated with adverse effects, though use in the first trimester should only occur if clearly indicated. Caution is advised for nursing mothers, as it is unknown if the drug is excreted in human milk.

Regulatory documents state the product is contraindicated in patients with known hypersensitivity to clotrimazole or any component of the preparation. The topical powder is not for ophthalmic use and should not be used in the eyes. If irritation or sensitivity develops, official guidance is that use should be discontinued.

Overdose and Emergency Response

The official regulatory profile for Candid powder (Clotrimazole) indicates a minimal risk of acute intoxication following dermal application. Due to the active ingredient's minimal systemic absorption through the skin, acute overdosage from using the powder topically is classified as unlikely and is not expected to lead to a life-threatening situation.

Overdose guidance focuses primarily on the actions required in the event of accidental oral ingestion of the powder.

Documented Manifestations and Actions

Feature Official Regulatory Guidance
Overdose Presentations Following accidental oral ingestion, documented manifestations are dizziness, nausea, and vomiting.
Urgent Medical Help Required Seek emergency medical attention or contact a Poison Control Center right away if the powder is swallowed accidentally.
Antidote Status No specific antidote is known according to regulatory labeling.

Management for accidental ingestion is supportive. Routine measures such as gastric lavage should be considered only if clinical symptoms become apparent or if a life-threatening amount of the product has been ingested. Furthermore, the regulatory guidance specifies that any such procedure must include adequate airway protection. These official statements define the necessary emergency response without providing clinical advice.

Therapeutic Uses of Candid powder

Candid Powder: Main Uses and Benefits

Candid powder, which contains the established antifungal ingredient clotrimazole, is indicated for the topical management of various superficial fungal infections of the skin.

  • Dermatophyte Infections: It is used to help address common infections caused by dermatophytes, including athlete’s foot (tinea pedis), ringworm (tinea corporis), and jock itch (tinea cruris). The powder formulation may be particularly suitable for managing infections in intertriginous areas—skin folds where moisture and perspiration accumulate.
  • Cutaneous Candidiasis: The product is also employed in the treatment of cutaneous candidiasis (yeast infection) affecting the skin.
  • Adjuvant Therapy: The powder may be used as an adjunct to other antifungal treatments or as a possible preventative agent for skin infections, especially in areas prone to high moisture levels, which supports a neutral and dry environment for the skin.

Quick Facts

  • Primary Use: Management of fungal skin infections, including ringworm and athlete's foot.
  • Therapeutic Role: Helps resolve symptoms associated with dermatophytosis and cutaneous candidiasis.
  • Key Benefit: Supports a dry environment, which is favorable for managing fungal infections in skin folds.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

The eligibility for using Candid powder, a topical Clotrimazole formulation, is defined by regulatory agencies based primarily on a key exclusion and specific population restrictions.

Eligibility Scope

Classification Status based on Official Labeling
Populations for whom use is allowed Adults and Older Adults (Geriatric patients)
Populations for whom use is NOT recommended Pregnant women in the first trimester; Children under 2 years of age.
Populations for whom use is contraindicated Individuals with known hypersensitivity or allergy to clotrimazole or any other ingredient in the powder.

Eligibility Classifications (High-Level)

Age-Related Eligibility Rules

  • Children under 2 years: Use is restricted and officially not recommended unless directed by a doctor.
  • Adults and Older Adults: Use is established with no special restrictions or dosage adjustments noted.

Pregnancy and Lactation Eligibility

  • Pregnancy (First Trimester): Use is generally not recommended; to be used only if clearly indicated.
  • Lactation: Caution should be exercised; it is officially unknown whether the drug is excreted in human milk, and use on the breast area should be avoided.

Connection to the overall eligibility profile Official regulatory documents define who cannot use this medicine mainly by the absolute contraindication of known ingredient allergies. Eligibility for children under two and women in the first trimester of pregnancy is restricted due to insufficient data or an abundance of caution, which is typical for minimally absorbed topical agents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Candid powder (Topical Clotrimazole 1%) establishes a highly localized interaction structure due to the negligible systemic absorption of the active ingredient. Peak serum concentrations following topical application are below the level required to cause measurable systemic effects, which consequently results in no documented clinical warnings for drug–drug interactions involving liver enzymes or drug transporters.

Interaction scope

Category Official Regulatory Information
Medicinal product categories with documented interactions: None. The only documented interaction is with a non-medicinal substance.
Specific interacting medicines (if explicitly listed): None.
Mechanistic basis of interactions (only if stated in label): Physical/chemical interaction leading to material damage/deterioration of the substance.
Timing-based interaction rules (if applicable): Latex Barrier Contraceptives: Alternative precautions must be used for a period of at least five days following the application of the product to the genital area.
Interaction-related restrictions: The use of latex condoms and diaphragms is restricted immediately following and for a defined period after application in the region.

Interaction classifications (high-level)

Category Official Regulatory Information
Interaction severity classification (as defined in official documents): The interaction is classified as reducing the effectiveness and safety of the contraceptive device.
Regulatory basis (EMA / FDA / etc.): Information is derived from official regulatory and government-cited patient information for topical clotrimazole formulations.
Interaction-context constraints (as defined in official documents): The restriction applies specifically when the product is used on the genital area (vulva or penis).

Resulting interaction structure

Official interaction statements:

  • Regulatory labeling documents the potential for the product to physically interact with latex products, including condoms and diaphragms.
  • This physical interaction may result in the reduction of the effectiveness and safety of the contraceptive device.
  • No known or documented clinically significant drug–drug interactions are listed in the product’s regulatory interaction profile involving systemic drugs.

Connection to the overall interaction profile (2–4 sentences): The regulatory profile is defined by a non-systemic constraint involving barrier contraception. Due to the minimal absorption of the active ingredient, the product does not carry official warnings regarding interactions with medicinal products, metabolic enzymes, or drug transporters. This interaction structure is consistently reported across authoritative regulatory documents.

Mechanism of Action

How Candid Powder Works: Antifungal Mechanism

Clotrimazole, the active agent, operates via a highly selective pharmacodynamic mechanism focused on disrupting the structure and function of the fungal cell.

Targeting the Ergosterol Biosynthesis Pathway

The drug functions as a molecular inhibitor by binding to the fungal enzyme lanosterol 14-alpha-demethylase (CYP51). This interaction blocks a crucial step in the ergosterol biosynthesis pathway, which is necessary for the construction and maintenance of the fungal cytoplasmic membrane. This blockade results in a reduction of ergosterol synthesis and the accumulation of toxic precursor sterols within the cell.

Fungal Membrane Integrity Failure

The depletion of ergosterol, combined with the buildup of toxic intermediates, causes the fungal cell's cytoplasmic membrane to lose its structural integrity and functional control over selective permeability. This physiological failure results in internal components, such as potassium ions, leaking out, culminating in fungistatic (growth-arresting) or fungicidal (cell-killing) effects.

️ Physical Support for Antifungal Action

Beyond the pharmacological action, the powder formulation provides a physical mechanism through moisture absorption at the application site. This establishes a localized microenvironment less favorable for fungal proliferation, supporting the drug's primary pharmacological action.

Dosage and Administration Information

The administration of Candid powder (Clotrimazole 1% topical) is for external use only on the skin surface. The medicine is applied as a thin layer to the affected area and the surrounding skin margins, ensuring comprehensive coverage without measurement by weight. The standard regimen involves application twice daily, once in the morning and once at night, a frequency pattern established for topical clotrimazole formulations.

Prior to application, the treatment area is thoroughly washed and dried to promote proper adherence. The application duration depends on the location of the fungal infection: for jock itch (tinea cruris), the period is typically two weeks of continuous use, while for athlete’s foot (tinea pedis) and ringworm (tinea corporis), it is four weeks. Completing the full duration is a standard practice, regardless of whether symptoms appear to resolve earlier.

This topical preparation is used for adults and children 2 years of age and older. Use in children under the age of two involves direction from a healthcare provider. This formulation is not effective for and not intended for use on the scalp or nails.

Administration Detail Standard Parameters
Route Topical, external use only
Dosing Frequency Twice daily (morning and night)
Preparation Wash and dry affected area thoroughly
Minimum Age 2 years old (unless physician-directed)
Duration (Tinea cruris) 2 consecutive weeks
Duration (Tinea pedis/corporis) 4 consecutive weeks

Recent Clinical Evidence

Research Evidence for Primary Fungal Skin Infections

The research base for the active ingredient, Clotrimazole, consists of Randomized Controlled Trials (RCTs) and Systematic Reviews exploring its use for Tinea infections and cutaneous yeast infections in adults and children. Researchers primarily monitored Mycological Cure (fungal elimination) and Clinical Outcomes (symptom evolution). Studies describe patterns where the active ingredient group was associated with different outcome measurements compared to inactive control groups.

Comparative research explored the timing of outcomes in relation to other topical agents, noting that the duration of application studied was sometimes longer, though final sustained outcome measurements were described as similar in the observed populations.

Evidence for Use in Skin Folds and High-Moisture Conditions

The powder formulation was studied specifically for application in areas of excess moisture (intertriginous areas). Research explored the powder's role as an adjuvant therapy, with some studies observing different complete cure measurements when the powder was used alongside the cream formulation. Other trials investigated its application for prophylaxis (use in a high-risk setting), reporting data showing patterns related to fungal presence and local skin condition in observed populations, such as under orthopedic casts.

Overall Quality of Evidence and Key Limitations

The evidence related to the active ingredient's general use is well-established. However, certain limitations exist: most foundational comparative evidence is derived from studies using cream or solution formulations, meaning those results apply only to the populations and formulation studied. Follow-up periods assessed for long-term outcomes are limited, and data for certain groups, such as children under the age of two years for some infections, remain limited or uncertain.

Frequently Asked Questions (FAQ)

Common questions about Candid powder (FAQ)

Q: What if I miss an application of the powder?

If an application is missed, the official patient information suggests applying it as soon as it is remembered. However, if it is nearly time for the next scheduled application, the information suggests skipping the missed one entirely. It is important not to use a double application to compensate, but instead return to the regular application schedule.

Q: What kind of fungal infections does Candid powder treat?

According to official regulatory labeling, this product is intended to treat and help cure most common superficial skin infections. This includes athlete’s foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis).

Q: Are there any foods or drinks I need to avoid while using this powder?

Official regulatory documents and patient safety information for topical clotrimazole do not list any known interactions with food or drinks. Due to the minimal absorption of the medicine into the body from the skin, diet restrictions are not typically noted in the product information.

Q: What should I do if I accidentally swallow some Candid powder?

Candid powder is strictly designated for external use on the skin. If the product is swallowed, it is recommended to seek immediate medical assistance. You should contact a Poison Control Center right away for guidance on next steps.

Q: How much powder should I apply each time?

Official directions state to apply a thin layer of the powder over the treatment area. Use enough to cover the entire affected area and the surrounding skin, as directed in the product labeling. The product should be applied to the skin surface only.

How should Candid powder be stored and disposed of?

How to Store and Dispose of Candid Powder (Clotrimazole)

Candid Dusting Powder must be stored and disposed of according to the explicit instructions provided in official regulatory documentation.

Mandatory Storage Conditions

Requirement Official Instruction
Temperature Store below 30°C.
Protection Must be protected from light.
Packaging Store the product in the original carton.
Child Safety Keep out of the reach and sight of children.
Stability Do not use after the expiry date stated on the label.

Disposal Instructions

Expired or unused medicine must be discarded responsibly to protect the environment. Regulatory guidance states the medicine should not be disposed of via wastewater or household waste. Patients are instructed to ask the pharmacist how to dispose of medicines no longer required or dispose of the material in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Candid powder found in:

A-Z Index: